Varenicline was approved as a replacement therapy for smoking back in 2007 in Australia, the uptake for varenicline has remained high despite issues associated with patient adherence and access to the therapy. In this interview, touchRESPIRATORY were delighted to speak with Prof. Michael Abramson (Monash University, Victoria, Australia) to discuss his randomized, placebo-controlled trial evaluating the effectiveness and safety of varenicline in smokers admitted to hospital.
The abstract ‘Varenicline and nicotine replacement therapy for smokers admitted to hospitals: a randomized, placebo-controlled trial.‘ was presented at ERS 2023, 9 – 13 September 2023.
- What impact has varenicline had as a replacement therapy for smokers in Australia, since approval? (0:31)
- What issues surround adherence to varenicline? (2:06)
- What were the aims and design of your trial? (3:36)
- What were the key findings and take-home messages? (5:40)
- How significant are follow-up sessions and behavioural support in smoking cessation treatment? (8:10)
Disclosures: Michael Abramson discloses consulting for Sanofi; receiving grant/research support from Pfizer, Boehringer-Ingelheim, GSK, and Sanofi; participating in speaker’s bureaus with GSK; and the VANISH trial was funded by the Global Research Awards for Nicotine Dependence (GRAND), an independently reviewed competitive grants program supported by Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS Annual Meeting.
Share this Video
Related Videos In Lung Cancer
A study of varenicline and nicotine replacement therapy for smokers admitted to hospital in Australia: Michael Abramson, ERS 2023
Varenicline was approved as a replacement therapy for smoking back in 2007 in Australia, the uptake for varenicline has remained high despite issues associated with patient adherence and access to the therapy. In this interview, touchRESPIRATORY were delighted to speak with Prof. Michael Abramson (Monash University, Victoria, Australia) to discuss his randomized, placebo-controlled trial evaluating […]
Daniel Steinfort, WCBIP 2022: Findings from the SEISMIC Study
The SEISMIC study investigated lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with locally advanced non-small cell lung cancer (NSCLC). touchRESPIRATORY were delighted to speak with Dr. Daniel Steinfort (Royal Melbourne Hospital, Melbourne, Australia) to learn more around the aims, design and findings from the study and the importance of these findings […]
Paulo Rodrigues Santos, ERS 2022: Immunosuppressive Factors Affecting Anti-PD-1 Therapy in Phase IIIB/IV Non-small Cell Lung Cancer
touchRESPIRATORY caught up with Dr. Paulo Rodrigues Santos (University of Coimbra, Coimbra, Portugal) to discuss the challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer, the cellular and plasmatic immunosuppressive factors that affect the outcome of anti-PD-1 therapy and the data supporting the strategies used to overcome these immunosuppressive […]